Managing Osteoporosis in COPD

Lilan      Shen; Juanqin      Lv; Jie      Li; Jing      Zhou; Xiaomin      Wang

doi:10.2174/1871530323666230913105752

Abstract

Chronic obstructive pulmonary disease (COPD) is a serious respiratory disease with high morbidity, disability and mortality worldwide. Every year, many people die from the disease or its comorbidities. Osteoporosis is a common complication of COPD, which can lead to increased fractures in COPD patients, aggravate the disease, and then bring great pain and burden to patients. The possible factors leading to osteoporosis in COPD patients include systemic inflammation, corticosteroid use, vitamin D deficiency, physical inactivity, tobacco exposure, lower bone mineral density, hypogonadism, hypoxia, and anemia. In clinical practice, the rate of diagnosis and treatment of osteoporosis in patients with COPD is low. Several studies demonstrated that treating osteoporosis with bisphosphonates could improve bone density, make breathing easier, and improve the quality of life of COPD patients. However, no studies have examined the effect of anti-osteoporosis therapy on fracture prevention in COPD patients. More research is needed to clarify how to implement holistic medical interventions in COPD patients with osteoporosis. We recommend that every COPD patient be screened for osteoporosis and treated with standard medications for primary osteoporosis.

« Previous Next »

[1]
The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 Report). 2021. Available from: http://www.goldcopd.org

[2]
Hillas, G.; Perlikos, F.; Tsiligianni, I.; Tzanakis, N. Managing comorbidities in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.,  2015, 10, 95-109.
 [PMID: 25609943]

[3]
World Health Organization (WHO). The top 10 causes of death.  Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-

[4]
GBD 2017 Causes of Death Collaborators. Global, regional and national age-sex specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systemic analysis for the Global Burden of Disease Study 2017. Lancet,  2018, 392, 1736-1788.
 [http://dx.doi.org/10.1016/S0140-6736(18)32203-7] [PMID: 30496103]

[5]
Rabe, K.F.; Watz, H. Chronic obstructive pulmonary disease. Lancet,  2017, 389(10082), 1931-1940.
 [http://dx.doi.org/10.1016/S0140-6736(17)31222-9] [PMID: 28513453]

[6]
Greulich, T.; Weist, B.J.D.; Koczulla, A.R.; Janciauskiene, S.; Klemmer, A.; Lux, W.; Alter, P.; Vogelmeier, C.F. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir. Med.,  2017, 132, 132-138.
 [http://dx.doi.org/10.1016/j.rmed.2017.10.007] [PMID: 29229085]

[7]
Cavaillès, A.; Brinchault-Rabin, G.; Dixmier, A.; Goupil, F.; Gut-Gobert, C.; Marchand-Adam, S.; Meurice, J.C.; Morel, H.; Person-Tacnet, C.; Leroyer, C.; Diot, P. Comorbidities of COPD. Eur. Respir. Rev.,  2013, 22(130), 454-475.
 [http://dx.doi.org/10.1183/09059180.00008612] [PMID: 24293462]

[8]
Inoue, D.; Watanabe, R.; Okazaki, R. COPD and osteoporosis: Links, risks, and treatment challenges. Int. J. Chron. Obstruct. Pulmon. Dis.,  2016, 11, 637-648.
 [http://dx.doi.org/10.2147/COPD.S79638] [PMID: 27099481]

[9]
Jesús Recio, I.; Díez-Manglano, J.; Francisco López, G.; José Antonio, D.P.; Pere, A.; José Manuel, V.A. Management of the COPD patient with comorbidities: An experts recommendation document. Int. J. Chron. Obstruct. Pulmon. Dis.,  2020, 15, 1015-1037.

[10]
Okazaki, R.; Watanabe, R.; Inoue, D. Osteoporosis associated with chronic obstructive pulmonary disease. J. Bone Metab.,  2016, 23(3), 111-120.
 [http://dx.doi.org/10.11005/jbm.2016.23.3.111] [PMID: 27622174]

[11]
Corlateanu, A.; Covantev, S.; Mathioudakis, A.G.; Botnaru, V.; Siafakas, N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir. Investig.,  2016, 54(6), 387-396.
 [http://dx.doi.org/10.1016/j.resinv.2016.07.001] [PMID: 27886849]

[12]
Kwon, H.; Kim, E. Factors contributing to quality of life in COPD patients in South Korea. Int. J. Chron. Obstruct. Pulmon. Dis.,  2016, 11, 103-109.
 [http://dx.doi.org/10.2147/COPD.S90566] [PMID: 26834467]

[13]
Zhang, M.; Yan, D.W.; Zhang, Q.L. The effect for COPD patients with osteoporosis and on lung function using alondronate. Zhongguo Guzhi Shusong Zazhi,  2004, 10, 340-343.

[14]
Yuan, H.; Li, J.; Weng, Y.Q. The efficacy of zoledronic acid on osteoporosis and pulmonary function in COPD patients. Zhongguo Guzhi Shusong Zazhi,  2019, 25, 358-361.

[15]
OuYang, J.F.; Li, B.Q.; Xuan, W.H. Clinical effectiveness of Zoledronic acid in the treatlnent Of senile osteoporosis patients with COPD. Zhongguo Guzhi Shusong Zazhi,  2019, 25, 1142-1145.

[16]
Liu, L.L.; Zhang, C.C.; Xiong, W. Effect of Alendronate combined with Caltrate D on COPD complicated with osteoporosis and on pulmonary function. Zhongguo Laonianxue Zazhi,  2021, 41, 3426-3429.

[17]
Chen Yi, W.; Ramsook, A.H.; Coxson, H.O. Prevalence and risk factors for ostoporosis in individuaIs with chronic obstructive pulmonary disease: A systematic review and meta-analysjs. Chest,  2019, 156, 1092-1110.

[18]
Rao, C.M.; Singh, P.; Maikap, D.; Padhan, P. Musculoskeletal disorders in chronic obstructive airway diseases: A neglected clinical entity. Mediterr. J. Rheumatol.,  2021, 32(2), 118-123.
 [http://dx.doi.org/10.31138/mjr.32.2.118] [PMID: 34447907]

[19]
Khan, A.H.; Bitar, A.N.; Syed Sulaiman, S.A.; Ali, I.A.H.; Khan, I. Osteoporosis among patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis of prevalence, severity, and therapeutic outcomes. J. Pharm. Bioallied Sci.,  2019, 11(4), 310-320.
 [http://dx.doi.org/10.4103/jpbs.JPBS_126_19] [PMID: 31619912]

[20]
Cecins, E.; Cavalheri, V.; Taaffe, D.R.; Hill, A.M.; Hug, S.; Hill, K. Prevalence of suspected poor bone health in people with chronic obstructive pulmonary disease – a cross-sectional exploratory study. Chron. Respir. Dis.,  2022, 19, 14799731221120429.
 [http://dx.doi.org/10.1177/14799731221120429] [PMID: 36069319]

[21]
Kjensli, A.; Falch, J.A.; Ryg, M.; Blenk, T.; Armbrecht, G.; Diep, L.M.; Ellingsen, I. High prevalence of vertebral deformities in COPD patients: Relationship to disease severity. Eur. Respir. J.,  2009, 33(5), 1018-1024.
 [http://dx.doi.org/10.1183/09031936.00073908] [PMID: 19129288]

[22]
Ogura-Tomomatsu, H.; Asano, K.; Tomomatsu, K.; Miyata, J.; Ohmori, N.; Kodama, M.; Ueda, S.; Takihara, T.; Tanaka, K.; Kamiishi, N.; Suzuki, Y.; Fukunaga, K.; Oguma, T.; Sayama, K.; Betsuyaku, T. Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD,  2012, 9(4), 332-337.
 [http://dx.doi.org/10.3109/15412555.2012.667850] [PMID: 22489911]

[23]
de Vries, F.; van Staa, T.P.; Bracke, M.S.; Cooper, C.; Leufkens, H.G.; Lammers, J.W. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur. Respir. J.,  2005, 25(5), 879-884.
 [http://dx.doi.org/10.1183/09031936.05.00058204] [PMID: 15863646]

[24]
Li, Y.; Gao, H.; Zhao, L.; Wang, J. Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation. Clin. Respir. J.,  2022, 16(7), 487-496.
 [http://dx.doi.org/10.1111/crj.13514] [PMID: 35688435]

[25]
Lippi, L.; Folli, A.; Curci, C.; D’Abrosca, F.; Moalli, S.; Mezian, K.; de Sire, A.; Invernizzi, M. Osteosarcopenia in patients with chronic obstructive pulmonary diseases: Which pathophysiologic implications for rehabilitation? Int. J. Environ. Res. Public Health,  2022, 19(21), 14314.
 [http://dx.doi.org/10.3390/ijerph192114314] [PMID: 36361194]

[26]
Berglundh, S.; Malmgren, L.; Luthman, H.; McGuigan, F.; Åkesson, K. C-reactive protein, bone loss, fracture, and mortality in elderly women: A longitudinal study in the OPRA cohort. Osteoporos. Int.,  2015, 26(2), 727-735.
 [http://dx.doi.org/10.1007/s00198-014-2951-7] [PMID: 25410434]

[27]
Liang, B.; Feng, Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine,  2012, 42(1), 190-195.
 [http://dx.doi.org/10.1007/s12020-011-9583-x] [PMID: 22198912]

[28]
Huo, J The research about serum IL6 and c-reactive protein in elderly Osteoporosis patients with COPD. Chinese Med. Clin.,  2018, 18, 2104-2106.

[29]
Yang, J.J.; Cheng, C.Q.; Zhao, G.Y. Chronic obstructive pulmonary disease and osteoporosis. Zhongguo Guzhi Shusong Zazhi,  2020, 26, 1378-1381.

[30]
Zhang, L.; Sun, Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front. Endocrinol.,  2021, 12, 724911.
 [http://dx.doi.org/10.3389/fendo.2021.724911] [PMID: 34650518]

[31]
Sarkar, M.; Bhardwaj, R.; Madabhavi, I.; Khatana, J. Osteoporosis in chronic obstructive pulmonary disease. Clin. Med. Insights Circ. Respir. Pulm. Med.,  2015, 9, CCRPM.S22803.
 [http://dx.doi.org/10.4137/CCRPM.S22803] [PMID: 25788838]

[32]
Sertpoyraz, F.M.; Deniz, S. Bone mineral density and vitamin D levels in patients with group a COPD. Aging Male,  2020, 23(5), 873-878.
 [http://dx.doi.org/10.1080/13685538.2019.1612869] [PMID: 31084421]

[33]
Kokturk, N.; Baha, A.; Oh, Y.M.; Young Ju, J.; Jones, P.W. Vitamin D deficiency: What does it mean for chronic obstructive pulmonary disease (COPD)? a compherensive review for pulmonologists. Clin. Respir. J.,  2018, 12(2), 382-397.
 [http://dx.doi.org/10.1111/crj.12588] [PMID: 27925404]

[34]
Sanket, S.; Madireddi, J.; Stanley, W.; Sura, P.; Prabhu, M. Relation between vitamin d deficiency and severity of chronic obstructive pulmonary disease-A case control study. J. Clin. Diagn. Res.,  2016, 10(1), OC16-OC19.
 [http://dx.doi.org/10.7860/JCDR/2016/15404.7097] [PMID: 26894108]

[35]
Lu, P.C.; Yang, Y.H.; Guo, S.E.; Yang, T.M. Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease-a nationwide retrospective study. Osteoporos. Int.,  2017, 28(1), 359-367.
 [http://dx.doi.org/10.1007/s00198-016-3732-2] [PMID: 27519532]

[36]
Oshagbemi, O.A.; Burden, A.M.; Shudofsky, K.N.; Driessen, J.H.M.; Vestergaard, P.; Krings, A.; Franssen, F.M.E.; van den Bergh, J.; de Vries, F. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease. Bone,  2018, 110, 238-243.
 [http://dx.doi.org/10.1016/j.bone.2018.02.007] [PMID: 29462672]

[37]
Price, D.B.; Voorham, J.; Brusselle, G.; Clemens, A.; Kostikas, K.; Stephens, J.W.; Park, H.Y.; Roche, N.; Fogel, R. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: Matched cohort study. NPJ Prim. Care Respir. Med.,  2019, 29(1), 38.
 [http://dx.doi.org/10.1038/s41533-019-0150-x] [PMID: 31659161]

[38]
Chiu, K.L.; Lee, C.C.; Chen, C.Y. Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan. Sci. Rep.,  2021, 11(1), 724.
 [http://dx.doi.org/10.1038/s41598-020-80815-y] [PMID: 33436973]

[39]
Ozcakir, S.; Sigirli, D.; Ursavas, A.; Uzaslan, E. COPD and osteoporosis: Associated factors in patients treated with inhaled corticosteroids. Int. J. Chron. Obstruct. Pulmon. Dis.,  2020, 15, 2441-2448.
 [http://dx.doi.org/10.2147/COPD.S274728] [PMID: 33116459]

[40]
van Staa, T.P.; Leufkens, H.G.M.; Abenhaim, L.; Zhang, B.; Cooper, C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology,  2000, 39(12), 1383-1389.
 [http://dx.doi.org/10.1093/rheumatology/39.12.1383] [PMID: 11136882]

[41]
Yohannes, A.M.; Ershler, W.B. Anemia in COPD: A systematic review of the prevalence, quality of life, and mortality. Respir. Care,  2011, 56(5), 644-652.
 [http://dx.doi.org/10.4187/respcare.01002] [PMID: 21276321]

[42]
Korkmaz, U.; Korkmaz, N.; Yazici, S.; Erkan, M.; Baki, A.E.; Yazici, M.; Ozhan, H.; Ataoğlu, S. Anemia as a risk factor for low bone mineral density in postmenopausal Turkish women. Eur. J. Intern. Med.,  2012, 23(2), 154-158.
 [http://dx.doi.org/10.1016/j.ejim.2011.11.009] [PMID: 22284246]

[43]
Kameyama, N.; Chubachi, S.; Sasaki, M.; Tsutsumi, A.; Irie, H.; Sakurai, K.; Sayama, K.; Nakamura, H.; Asano, K.; Betsuyaku, T.; Fukunaga, K. Predictive and modifying factors of bone mineral density decline in patients with COPD. Respir. Med.,  2019, 148, 13-23.
 [http://dx.doi.org/10.1016/j.rmed.2019.01.005] [PMID: 30827469]

[44]
Arnett, T.R. Acidosis, hypoxia and bone. Arch. Biochem. Biophys.,  2010, 503(1), 103-109.
 [http://dx.doi.org/10.1016/j.abb.2010.07.021] [PMID: 20655868]

[45]
Rodríguez-Gómez, I.; Gray, S.R.; Ho, F.K.; Petermann-Rocha, F.; Welsh, P.; Cleland, J.; Iliodromiti, S.; Ara, I.; Pell, J.; Sattar, N.; Ferguson, L.D.; Celis-Morales, C. Osteoporosis and its association with cardiovascular disease, respiratory disease, and cancer: Findings from the uk biobank prospective cohort study. Mayo Clin. Proc.,  2022, 97(1), 110-121.
 [http://dx.doi.org/10.1016/j.mayocp.2021.07.019] [PMID: 34996542]

[46]
Kakoullis, L.; Sampsonas, F.; Karamouzos, V.; Kyriakou, G.; Parperis, K.; Papachristodoulou, E.; Christophi, C.; Lykouras, D.; Kalogeropoulou, C.; Daoussis, D.; Panos, G.; Velissaris, D.; Karkoulias, K.; Spiropoulos, K. The impact of osteoporosis and vertebral compression fractures on mortality and association with pulmonary function in COPD: A meta-analysis. Joint Bone Spine,  2022, 89(1), 105249.
 [http://dx.doi.org/10.1016/j.jbspin.2021.105249] [PMID: 34265476]

[47]
Munhoz da Rocha Lemos Costa, T.; Costa, F.M.; Hoffman Jonasson, T.; Aguiar Moreira, C.; Boguszewski, C.L.; Cunha Borges, J.L.; Zeghbi Cochenski Borba, V. Bone mineral density and vertebral fractures and their relationship with pulmonary dysfunction in patients with chronic obstructive pulmonary disease. Osteoporos. Int.,  2018, 29(11), 2537-2543.
 [http://dx.doi.org/10.1007/s00198-018-4643-1] [PMID: 30043107]

[48]
Gazzotti, M.R. Frequency of osteopomsis and vertebral fractures in chronic obstmctive pulmonary disease(COPD) patients. Arch. Bronconeumol.,  2019, 55, 252-257.

[49]
Watanabe, K.; Onoue, A.; Kubota, K.; Higashi, N.; Hayashi, T.; Tsuda, T.; Omori, H. Association between airflow limitation severity and reduced bone mineral density in Japanese men. Int. J. Chron. Obstruct. Pulmon. Dis.,  2019, 14, 2355-2363.
 [http://dx.doi.org/10.2147/COPD.S213746] [PMID: 31695355]

[50]
Majumdar, S.R.; Villa-Roel, C.; Lyons, K.J.; Rowe, B.H. Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir. Med.,  2010, 104(2), 260-266.
 [http://dx.doi.org/10.1016/j.rmed.2009.09.013] [PMID: 19828305]

[51]
Shane, E.; Silverberg, S.J.; Donovan, D.; Papadopoulos, A.; Staron, R.B.; Addesso, V.; Jorgesen, B.; McGregor, C.; Schulman, L. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am. J. Med.,  1996, 101(3), 262-269.
 [http://dx.doi.org/10.1016/S0002-9343(96)00155-6] [PMID: 8873487]

[52]
Lee, I.S.; Leem, A.Y.; Lee, S.H.; Rhee, Y.; Ha, Y.; Kim, Y.S. Relationship between pulmonary function and bone mineral density in the korean national health and nutrition examination survey. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.),  2016, 31(5), 899-909.
 [http://dx.doi.org/10.3904/kjim.2015.127] [PMID: 27604798]

[53]
Vikjord, S.A.A.; Brumpton, B.M.; Mai, X.M.; Bhatta, L.; Vanfleteren, L.; Langhammer, A. The association of bone mineral density with mortality in a COPD Cohort. The HUNT study, norway. COPD,  2019, 16(5-6), 321-329.
 [http://dx.doi.org/10.1080/15412555.2019.1685482] [PMID: 31709837]

[54]
Chua, J.R.; Tee, M.L. Association of sarcopenia with osteoporosis in patients with chronic obstructive pulmonary disease. Osteoporos. Sarcopenia,  2020, 6(3), 129-132.
 [http://dx.doi.org/10.1016/j.afos.2020.07.004] [PMID: 33102806]

[55]
Lehouck, A.; Boonen, S.; Decramer, M.; Janssens, W. COPD, bone metabolism, and osteoporosis. Chest,  2011, 139(3), 648-657.
 [http://dx.doi.org/10.1378/chest.10-1427] [PMID: 21362651]

[56]
Janssens, W.; Lehouck, A.; Carremans, C.; Bouillon, R.; Mathieu, C.; Decramer, M. Vitamin D beyond bones in chronic obstructive pulmonary disease: Time to act. Am. J. Respir. Crit. Care Med.,  2009, 179(8), 630-636.
 [http://dx.doi.org/10.1164/rccm.200810-1576PP] [PMID: 19164701]

[57]
Kanis, J.A.; McCloskey, E.V.; Johansson, H.; Cooper, C.; Rizzoli, R.; Reginster, J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int.,  2013, 24(1), 23-57.
 [http://dx.doi.org/10.1007/s00198-012-2074-y] [PMID: 23079689]

[58]
Smith, B.J.; Laslett, L.L.; Pile, K.D.; Phillips, P.J.; Phillipov, G.; Evans, S.M.; Esterman, A.J.; Berry, J.G. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron. Respir. Dis.,  2004, 1(3), 131-137.
 [http://dx.doi.org/10.1191/1479972304cd025oa] [PMID: 16281654]

[59]
The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 Report). 2019. Available from: http://www.goldcopd.org

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871530323666230913105752	Print ISSN 1871-5303
Publisher Name Bentham Science Publisher	Online ISSN 2212-3873

Endocrine, Metabolic & Immune Disorders - Drug Targets

Managing Osteoporosis in COPD

Abstract Play Pause

Related Journals

Related Books

Abstract